Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to $1.7 million.

  • Mereo BioPharma's Share-based Compensation fell 138.25% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year increase of 1317.09%. This contributed to the annual value of $7.4 million for FY2024, which is 5008.12% up from last year.
  • Per Mereo BioPharma's latest filing, its Share-based Compensation stood at $1.7 million for Q3 2025, which was down 138.25% from $2.1 million recorded in Q2 2025.
  • Mereo BioPharma's 5-year Share-based Compensation high stood at $2.3 million for Q1 2025, and its period low was $815000.0 during Q4 2023.
  • Its 3-year average for Share-based Compensation is $1.7 million, with a median of $1.7 million in 2025.
  • In the last 5 years, Mereo BioPharma's Share-based Compensation skyrocketed by 12142.1% in 2024 and then crashed by 138.25% in 2025.
  • Over the past 3 years, Mereo BioPharma's Share-based Compensation (Quarter) stood at $815000.0 in 2023, then surged by 85.89% to $1.5 million in 2024, then increased by 13.0% to $1.7 million in 2025.
  • Its Share-based Compensation was $1.7 million in Q3 2025, compared to $2.1 million in Q2 2025 and $2.3 million in Q1 2025.